In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5β1-selective peptidomimetic FR366
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vivo biokinetic and metabolic characterization of the 68Ga-labelled α5β1-selective peptidomimetic FR366
Authors
Keywords
α5β1, Integrin antagonist, Peptidomimetics, PET imaging
Journal
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
Volume 43, Issue 5, Pages 953-963
Publisher
Springer Nature
Online
2015-10-25
DOI
10.1007/s00259-015-3218-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brag2 differentially regulates β1- and β3-integrin-dependent adhesion in endothelial cells and is involved in developmental and pathological angiogenesis
- (2014) Yosif Manavski et al. BASIC RESEARCH IN CARDIOLOGY
- Pharmacophoric Modifications Lead to Superpotent αvβ3 Integrin Ligands with Suppressed α5β1 Activity
- (2014) Stefanie Neubauer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective Imaging of the Angiogenic Relevant Integrins α5β1 and αvβ3
- (2013) Stefanie Neubauer et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Functionalizing αvβ3- or α5β1-Selective Integrin Antagonists for Surface Coating: A Method To Discriminate Integrin Subtypes In Vitro
- (2012) Florian Rechenmacher et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Integrin 5 1 Plays a Critical Role in Resistance to Temozolomide by Interfering with the p53 Pathway in High-Grade Glioma
- (2012) H. Janouskova et al. CANCER RESEARCH
- 68Ga-NODAGA-RGD is a suitable substitute for 18F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process
- (2012) Karolin Pohle et al. NUCLEAR MEDICINE AND BIOLOGY
- The Primacy of β1 Integrin Activation in the Metastatic Cascade
- (2012) Hisashi Kato et al. PLoS One
- Integrins as therapeutic targets
- (2012) Simon L. Goodman et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
- (2011) Carlos Mas-Moruno et al. Anti-Cancer Agents in Medicinal Chemistry
- The role of β3-integrins in tumor angiogenesis: context is everything
- (2011) Stephen D Robinson et al. CURRENT OPINION IN CELL BIOLOGY
- The final steps of integrin activation: the end game
- (2010) Sanford J. Shattil et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Ligands for Mapping αvβ3-Integrin Expression in Vivo
- (2009) Margret Schottelius et al. ACCOUNTS OF CHEMICAL RESEARCH
- Integrin signalling at a glance
- (2009) D. S. Harburger et al. JOURNAL OF CELL SCIENCE
- 1 Integrin Inhibition Dramatically Enhances Radiotherapy Efficacy in Human Breast Cancer Xenografts
- (2008) C. C. Park et al. CANCER RESEARCH
- Inhibition of Metastatic Outgrowth from Single Dormant Tumor Cells by Targeting the Cytoskeleton
- (2008) D. Barkan et al. CANCER RESEARCH
- Rational Design of Highly Active and Selective Ligands for the α5β1 Integrin Receptor
- (2008) Dominik Heckmann et al. CHEMBIOCHEM
- αvβ3 integrin and angiogenesis: a moody integrin in a changing environment
- (2008) Kairbaan Hodivala-Dilke CURRENT OPINION IN CELL BIOLOGY
- 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of αvβ3 integrin expression
- (2008) Clemens Decristoforo et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Three-dimensional MR mapping of angiogenesis with α5β1(ανβ3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model
- (2008) Anne H. Schmieder et al. FASEB JOURNAL
- Caveolin-1-dependent 1 integrin endocytosis is a critical regulator of fibronectin turnover
- (2008) F. Shi et al. JOURNAL OF CELL SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started